The China National Medical Products Administration has approved Zai Lab’s (NASDAQ:ZLAB) supplemental New Drug Application (sNDA) for ZEJULA (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
ZEJULA is also being evaluated in China for the treatment of patients with advanced or metastatic gastric cancer who failed prior treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.